MENU
IUGND
Stock ticker: OTC
PRICE
CHANGE
CAPITALIZATION

Imugene (IUGND) Ownership - Who owns Imugene?

Imugene Ltd specializes in a clinical-stage immuno-oncology company... Show more

Details

Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
58.61M
P/E Ratio
N/A
Total Cash
N/A
Projected Growth
N/A
Total Debt
N/A
Revenue
235.91K
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash/Share
N/A
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price

Fundamentals

IUGND
Capitalization
58.6M
P/E Ratio
N/A
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash
N/A
Total Cash/Share
N/A
Total Debt
N/A
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
N/A
Revenue
236K
ROE
N/A
Book Value
N/A
P/B Ratio
2.68
Cash Flow
N/A
Earnings
-0.6
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
N/A
Current Ratio
3.93
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-125.5M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-73.61
Shares Held By Institutions
N/A
Shares Outstanding - Current
225M
Total Liabilities
N/A
Total Volume MTD
N/A
Value
1
Gain YTD
-63.078
View a ticker or compare two or three
IUGND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details